Benjamin Cooper, MD, Examines Rationale Behind Combining TAK-676 With Pembrolizumab After Radiation in Select Solid Tumors

Video

Benjamin Cooper, MD, discussed an ongoing trial examining TAK-676 in combination with pembrolizumab after radiation therapy for patients with non–small cell lung cancer, head and neck cancer, and triple-negative breast cancer.

At the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Benjamin Cooper, MD, a radiation oncologist and director of Proton Therapy Services at NYU Langone Health, about a phase 1 trial in progress (NCT04879849) which is analyzing TAK-676 plus pembrolizumab (Keytruda) after radiation for patients with non–small cell lung, triple-negative breast, and squamous cell head and neck cancer that has progressed following checkpoint inhibitor therapy. He also discussed the mechanism of action of TAK-676 and dosing regimens for these patients.

Transcript:

TAK-676 is a sting agonist that is delivered intravenously. The idea [behind] combining it with pembrolizumab is to reinvigorate the immune system. We’re adding radiation in addition to that at 8 Gy times 3 to generate neoantigens to helpfully allow a systemic response.

This is a phase 1 trial looking at patients with head and neck squamous cell cancer, triple-negative breast cancer, and non–small cell lung cancer. These patients all have progressed on checkpoint inhibition, and this is a phase 1 dose-escalation trial of the TAK-676 molecule. Patients are enrolled after a positive biopsy; they are treated with 8 Gy times 3 to up to 3 sites with the intention of generating new antigens. Over 40 hours later, they’re treated with the checkpoint [inhibitor] pembrolizumab, as well as with TAK-676 and are assessed in 3 weeks cycles.

Reference

Cooper BT, Chmura SJ, Luke JJ, et al. TAK-676 in combination with pembrolizumab after radiation therapy in patients (pts) with advanced non–small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), or squamous-cell carcinoma of the head and neck (SCCHN): Phase 1 study design. J Clin Oncol. 2022;40(suppl 17): TPS2698. doi: 10.1200/JCO.2022.40.16_suppl.TPS2698

Recent Videos
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
According to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Earlier and more frequent talks about disabling ICDs with patients receiving end-of-life care and their families may help avoid excessive pain.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
AI-powered tools may help alleviate doctor burnout and give clinicians more time to directly engage with patients.
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Related Content